Continuous Bioprocessing Market Report Scope and Overview:

The Continuous Bioprocessing Market was valued at USD 405.15 Million in 2025 and is projected to reach USD 2,212.07 Million by 2035, registering a CAGR of 18.50% between 2026 and 2035.

The Continuous Bioprocessing Market is expanding as biomanufacturers move away from traditional batch operations toward perfusion-based upstream platforms and integrated downstream trains that run with fewer interruptions, smaller footprints and tighter process control. Growth reflects sustained monoclonal antibody and biosimilar output, a widening cell and gene therapy pipeline favoring compact, closed, single-use systems, and payer pressure to lower cost of goods through continuous chromatography and single-pass tangential flow filtration. Regulatory agencies continue encouraging process analytical technology and real-time release testing, while capacity investment by large biopharmaceutical manufacturers and contract manufacturing organizations reinforces equipment, consumables and automation software demand as suppliers expand global manufacturing footprints to keep pace with accelerating adoption.

⮞In March 2025, Sartorius advanced its continuous downstream capacity when it moved to nearly double chromatography system manufacturing and testing output at its Bangalore, India site, adding a new customer application center supporting large-scale biopharmaceutical purification.

U.S. Continuous Bioprocessing Market Outlook

The U.S. Continuous Bioprocessing Market was valued at approximately USD 130.09 Million in 2025 and is projected to reach USD 669.07 Million by 2035, registering a CAGR of 17.79% from 2026 to 2035.

The U.S. Continuous Bioprocessing Market benefits from a large installed base of biopharmaceutical manufacturers, contract development and manufacturing organizations and academic research centers that moved early into perfusion culture and continuous downstream purification. Sustained capital spending on monoclonal antibody, biosimilar and cell and gene therapy manufacturing capacity underpins steady equipment and consumables demand, and the Food and Drug Administration's long-standing support for process analytical technology pushes suppliers to tailor platforms to U.S. regulatory expectations. An extensive network of single-use component suppliers and contract manufacturers keeps adoption cycles short, with several facility expansions adding continuous processing capacity in both established biologics hubs and emerging manufacturing regions.

⮞In July 2026, Repligen expanded its continuous processing manufacturing capacity in Waltham, Massachusetts, adding production lines for XCell ATF perfusion devices and continuous chromatography columns to meet rising North American demand for perfusion-based upstream intensification.

By Offering: Bioreactors & Fermenters Lead, Process Analytical Technology & Automation Software Grows Fastest

The Bioreactors & Fermenters segment held the leading position in the Continuous Bioprocessing Market, supported by its role as the physical foundation on which perfusion intensification is built. Biomanufacturers replacing fed-batch vessels with perfusion-capable bioreactors gain higher cell densities, smaller working volumes and continuous nutrient exchange, reducing facility footprint while raising titer output per batch. Established suppliers continue refining single-use vessel designs and automated perfusion control loops, lowering the technical barrier for converting legacy fed-batch suites and keeping bioreactor spending among the largest line items within continuous platform investment.

Process Analytical Technology & Automation Software is growing fastest as biomanufacturers seek tighter, real-time control over continuous runs that can extend for weeks rather than days. Continuous processes carry greater consequences from undetected drift, so manufacturers are layering inline sensors and automation platforms onto bioreactors and chromatography skids to enable real-time release testing and reduce offline quality control sampling. Regulatory encouragement of quality-by-design reinforces this shift, while software vendors bundle data historian functionality that shortens validation timelines, making automation a fast-expanding category within the offering segmentation.

⮞In July 2026, Sartorius introduced an expanded BIOSTAT STR perfusion bioreactor lineup with integrated automation and data-historian connectivity, targeting biomanufacturers converting fed-batch suites to continuous upstream operation.

By Process: Upstream Processing Dominates, Downstream Processing Grows Fastest

Upstream Processing accounted for the larger share of the Continuous Bioprocessing Market, reflecting the breadth of perfusion culture adoption across both established biologics manufacturers and newer cell and gene therapy developers. Converting fed-batch bioreactors to perfusion-capable, continuous operation is comparatively straightforward relative to downstream conversion, and suppliers have responded with cell-retention devices, perfusion media and automated control loops that lower the technical barrier to adoption. The resulting larger installed base of perfusion-capable bioreactors sustains upstream's leading share of continuous platform spending.

Downstream Processing is the fastest-growing segment as manufacturers work to keep purification capacity in step with the higher titers that perfusion-intensified upstream platforms now deliver. Converting batch chromatography, virus filtration and polishing steps into continuous, multi-column trains requires specialized skids, control software and validation work, and manufacturers increasingly see this investment as unavoidable once upstream conversion raises output. Reduced resin and buffer consumption and smaller column footprints add a cost-saving incentive, lifting downstream spending faster than the now larger, more mature upstream category.

⮞In May 2025, Univercells Technologies launched the scale-X nitro controller, a compact unit operating its 200 and 600 square-meter fixed-bed bioreactors for viral vector and vaccine manufacturing, cutting reported production costs by up to 82 percent versus adherent methods.

By Application: Monoclonal Antibodies Dominate, Cell and Gene Therapy Grows Fastest

Monoclonal Antibodies remained the leading application within the Continuous Bioprocessing Market, reflecting the sheer scale of commercial antibody manufacturing and the cost pressure created by biosimilar competition. Antibody manufacturers were among the earliest adopters of perfusion culture and continuous chromatography because the production volumes involved make even modest per-gram cost reductions commercially significant. Established process platforms, well-characterized cell lines and a mature supplier base for antibody-specific resins and membranes continue to make monoclonal antibody production the largest and most consistent source of demand for continuous bioprocessing equipment and consumables.

Cell and Gene Therapy is growing fastest as developers favor compact, closed and automated processing platforms suited to small-batch, patient-specific or allogeneic production. Many cell and gene therapy products cannot justify the facility footprint of traditional batch suites, making continuous and intensified processing attractive for both viral vector and cell-based manufacturing. Developers also value the reduced manual intervention that continuous, automated platforms offer, since it lowers contamination risk in processes that are often more sensitive than conventional biologics manufacturing, a combination of factors sustaining the segment's rapid growth trajectory.

In February 2025, Repligen introduced a continuous perfusion-ready XCell ATF system configuration optimized for small-batch cell and gene therapy production, aimed at developers moving viral vector and cell-based manufacturing away from traditional batch suites.

By End User: Biopharmaceutical and Biotechnology Companies Dominate, Contract Manufacturing and Research Organizations Grow Fastest

Biopharmaceutical and Biotechnology Companies represented the dominant end-user segment, consistent with their direct ownership of manufacturing capacity for approved and late-stage pipeline products. These companies control the largest installed base of bioreactors, chromatography systems and filtration trains, and their capital expenditure decisions determine the pace at which continuous platforms replace legacy batch infrastructure. Internal process-development teams at large biopharmaceutical companies also continue to pioneer new continuous processing approaches before technology diffuses more broadly across the market, reinforcing this segment's leading position.

Contract Manufacturing and Research Organizations are growing fastest as smaller biotechnology sponsors increasingly outsource both process development and commercial manufacturing rather than building in-house capacity. Continuous bioprocessing platforms are particularly attractive to contract manufacturers because smaller, modular, single-use trains can be reconfigured between client programs more quickly than large stainless-steel batch suites, supporting the multi-product flexibility that contract manufacturing business models require. Expanding biologics and cell and gene therapy outsourcing, combined with continued capacity investment by contract manufacturers, continues to lift this segment's growth rate above the market average.

Regional Analysis

North America Continuous Bioprocessing Market Insights

North America led the Continuous Bioprocessing Market in 2025, holding the largest regional revenue share at about 38.50%. The region's scale reflects its depth of biologics manufacturing capacity, a broad contract development and manufacturing base, and academic research infrastructure built up over more than a decade of perfusion and continuous-purification deployment. Close geographic proximity between biomanufacturers and leading equipment and consumables producers keeps replacement and expansion cycles tight, reinforcing North America's lead across both established biologics hubs and newer manufacturing regions.

The United States accounted for the substantial majority of regional revenue, anchored by its concentration of leading antibody and biosimilar manufacturers, a well-established contract manufacturing network and sustained regulatory support for process analytical technology and continuous manufacturing pathways. Canada continued to contribute a smaller but growing share, supported by expanding biologics and cell and gene therapy manufacturing investment and government-backed life-sciences manufacturing initiatives that are encouraging domestic suppliers to adopt continuous and intensified processing platforms alongside traditional batch operations.

⮞In November 2025, Corning Incorporated expanded production of its Ascent fixed-bed bioreactor systems at its Durham, North Carolina site, adding capacity aimed at manufacturers converting monoclonal antibody and viral vector production to continuous, perfusion-based operation.

Europe Continuous Bioprocessing Market Insights

Europe held a meaningful share of global revenue, supported by an established base of biopharmaceutical manufacturers, contract development and manufacturing organizations and a long regulatory history of engaging with continuous manufacturing and process analytical technology initiatives through the European Medicines Agency. Regional manufacturers continue to invest in perfusion-capable bioreactors and continuous chromatography skids to support both legacy biologics portfolios and an expanding cell and gene therapy pipeline, while established European equipment and consumables suppliers continue to anchor regional technology development and supply chains.

Germany continued to lead regional demand at roughly 24.60% of European revenue, supported by its concentration of specialized biomanufacturing sites, major equipment and consumables producers and strong engineering capability in bioprocess automation. France, the United Kingdom, Italy and Spain continued to contribute meaningful regional revenue through established contract manufacturing networks, biosimilar production capacity and growing cell and gene therapy manufacturing investment, while Rest of Europe markets continued to expand more gradually as regional biomanufacturing infrastructure matures.

⮞In October 2025, Sartorius Stedim Biotech expanded continuous chromatography skid assembly capacity at its Goettingen, Germany site, adding test benches for multi-column purification trains to support European biosimilar and cell and gene therapy manufacturers.

Asia Pacific Continuous Bioprocessing Market Insights

Asia Pacific is growing at the fastest CAGR of around 19.80% between 2026 and 2035, with growth driven by expanding domestic biologics manufacturing capacity, rising contract manufacturing activity and government initiatives supporting biopharmaceutical self-sufficiency across China, India, Japan and South Korea. Regional manufacturers are increasingly adopting perfusion-based upstream platforms and continuous downstream purification to compete on cost and speed with established Western manufacturers, while international equipment and consumables suppliers continue expanding local manufacturing and technical-support footprints to serve the region's accelerating biomanufacturing investment.

China held a substantial share of regional revenue, supported by an expanding base of domestic biologics manufacturers and contract development and manufacturing organizations investing heavily in continuous and intensified processing capacity. India, Japan and South Korea continued to contribute growing regional revenue through expanding biosimilar and cell and gene therapy manufacturing investment, supported by government-backed biopharma infrastructure initiatives, while Southeast Asian markets continued to attract new equipment and consumables manufacturing investment from established global suppliers.

⮞In September 2025, WuXi Biologics brought a new continuous bioprocessing suite online at its Wuxi, China site, installing perfusion bioreactors and multi-column chromatography skids to support monoclonal antibody and biosimilar programs for regional and export clients.

MEA and Latin America Continuous Bioprocessing Market Insights

The Middle East and Africa showed steady growth, driven by expanding biomanufacturing infrastructure investment and national initiatives aimed at building regional biologics self-sufficiency. Saudi Arabia led Middle East and Africa demand, supported by national efforts to establish domestic biologics manufacturing capacity and reduce reliance on imported biopharmaceuticals, while South Africa and the United Arab Emirates continued to contribute through smaller-scale manufacturing and contract development investment, with regional regulatory bodies increasingly aligning quality expectations with international standards to attract further biomanufacturing investment.

Latin America also showed steady growth, driven by expanding insulin, biosimilar and vaccine manufacturing capacity and continued government support for regional pharmaceutical self-sufficiency. Brazil led Latin America demand, supported by large-scale biologics manufacturing investment and an established base of domestic and multinational producers, while Argentina, Mexico and Colombia continued to contribute smaller but growing regional revenue through expanding biosimilar manufacturing and contract development activity across the broader region.

⮞In October 2025, Getinge AB signed a technical-support agreement with a Saudi Arabian biologics manufacturer to commission single-use bioreactor and filtration skids, supporting the Kingdom's push to localize continuous biopharmaceutical production.

⮞In June 2025, Eppendorf SE expanded distribution and technical-service support for its single-use bioreactor and fermentation systems in Sao Paulo, Brazil, targeting biosimilar manufacturers adopting continuous and intensified upstream processing.

Market Dynamics

Growth Drivers: Rising Perfusion Adoption and Downstream Process Intensification

The Continuous Bioprocessing Market is driven by biomanufacturers' sustained shift toward perfusion-based upstream platforms, which allow smaller bioreactors to achieve higher volumetric productivity than traditional fed-batch systems. This intensification reduces facility footprint and capital expenditure per unit of output, an increasingly important consideration as biosimilar competition compresses margins across established monoclonal antibody franchises. Suppliers have responded with perfusion-ready bioreactor designs, cell-retention devices and perfusion media formulations that lower the technical risk of conversion, encouraging a widening base of manufacturers to adopt continuous or semi-continuous upstream operations across both new and existing manufacturing lines.

Parallel intensification of downstream purification, through continuous multi-column chromatography and single-pass tangential flow filtration, continues to reinforce overall market growth by allowing purification capacity to keep pace with higher upstream titers without proportional increases in resin, buffer or floor-space requirements. Regulatory encouragement of process analytical technology and real-time release testing further supports this shift, as agencies increasingly favor manufacturing approaches that demonstrate tighter, continuously monitored process control, reinforcing capital allocation toward integrated continuous platforms across both legacy biologics manufacturers and newer cell and gene therapy developers.

⮞In June 2026, Just - Evotec Biologics launched J.TRAIN, a turnkey continuous manufacturing offering that deploys prefabricated cleanrooms and automated process control at customer sites, claiming roughly ten times the productivity of conventional fed-batch manufacturing within under 10,000 square feet.

Restraints: High Capital Intensity and Technical Complexity of Continuous Platforms

Converting established batch manufacturing infrastructure to continuous operation requires substantial upfront investment in perfusion-capable bioreactors, continuous chromatography skids and the automation software needed to maintain real-time process control across extended run durations. Many mid-sized biopharmaceutical manufacturers and contract organizations find this capital commitment difficult to justify against the extended validation and regulatory filing work required to demonstrate equivalence with existing batch processes, which continues to slow broader adoption outside the largest, most capital-rich manufacturers.

Technical complexity also constrains adoption, since continuous processes must sustain stable cell culture and purification performance over days or weeks rather than the shorter, more easily controlled durations typical of batch operations. Maintaining sterility, avoiding genetic drift in extended perfusion culture and managing the data volume generated by continuous process analytical technology all require specialized expertise that remains concentrated among a relatively small pool of experienced bioprocess engineers, creating a talent bottleneck that continues to restrain the pace at which continuous bioprocessing platforms are implemented across the broader manufacturing base.

Opportunities: Expanding Cell and Gene Therapy Pipelines and Modular Facility Adoption

Expanding cell and gene therapy pipelines represent a significant opportunity for continuous bioprocessing suppliers, since many of these therapies are produced in small batches that favor compact, closed, automated platforms over large stainless-steel batch suites. Developers entering this space without legacy batch infrastructure are often more willing to adopt continuous processing from the outset, creating a growing addressable base of manufacturers with fewer internal barriers to continuous platform adoption than established biologics producers converting existing facilities.

Growing adoption of modular, single-use facility designs offers a second substantial opportunity, particularly for contract manufacturers and emerging-market biomanufacturers seeking to add capacity more quickly and with lower capital intensity than traditional stainless-steel construction allows. Modular facilities built around continuous, single-use platforms can be commissioned faster and reconfigured between client programs more readily, a combination of speed and flexibility that is encouraging wider adoption across contract manufacturing networks and newer manufacturing regions building biologics capacity from the ground up.

Continuous Bioprocessing Market key players are:

• Sartorius AG

• Thermo Fisher Scientific Inc.

• Repligen Corporation

• Merck KGaA (MilliporeSigma)

• Danaher Corporation (Cytiva, Pall)

• Getinge AB

• Eppendorf SE

• Corning Incorporated

• Entegris, Inc.

• FUJIFILM Biotechnologies

• Avantor, Inc.

• ABEC, Inc.

• Asahi Kasei Bioprocess

• Univercells Technologies

• GEA Group AG

Continuous Bioprocessing Market Report Scope: